Ahmad Anouti, MD, a pediatric resident at UT Southwestern Medical Center, spoke about the current treatment landscape for ...

Ahmad Anouti, MD, a pediatric resident at UT Southwestern Medical Center, spoke with Healio about treatments in the primary biliary cholangitis pipeline.He noted one therapy making strides in the ...

Conference call to provide business updates today, November 4 at 1:30 p.m. PT / 4:30 p.m. ET FOSTER CITY, Calif., November 04 ...

The expansion of the cholestatic pruritus market across the US will be driven by the introduction of innovative therapies, ...

In recent weeks, Gilead Sciences announced Health Canada's conditional approval of LYVDELZI (seladelpar) for primary biliary ...

Citizens JMP raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $95 from $81 and keeps an Outperform rating on the shares. Livmarli ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® ...

Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, ...

Mirum Pharmaceuticals MIRM reported earnings of 5 cents per share for the third quarter of 2025 against the Zacks Consensus ...

Among over 151,000 patients, use of GLP-1 drugs was linked to a lower risk of death compared with no use (adjusted HR 0.77, 95% CI 0.70-0.85, P <0.001), reported Babak J. Orandi, MD, PhD, MSc, of NYU ...

Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.

Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ...